1. Volume 153, Issue 3, Pages 541-548 (June 2019)
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor 
Martin Gore, Allan Hackshaw, William E. Brady, Richard T. Penson, Richard Zaino, W. Glenn McCluggage, Raji Ganesan, Nafisa Wilkinson, Timothy Perren, Ana Montes, Jeffrey Summers, Rosemary Lord, Graham Dark, Gordon Rustin, Melanie Mackean, Nicholas Reed, Sean Kehoe, Michael Frumovitz, Helen Christensen, Amanda Feeney, Jonathan Ledermann, David M. Gershenson 
Gynecologic Oncology 
Volume 153, Issue 3, Pages (June 2019)
DOI: /j.ygyno
Copyright © 2019 The Authors Terms and Conditions

2. Fig. 1
Overall survival according to the two main protocol-defined comparisons, ‘oxaliplatin + capecitabine versus no oxaliplatin + capecitabine’ and ‘bevacizumab versus no bevacizumab’, for all 50 patients (Panels A and B), and for patients with confirmed mEOC after central pathology review (Panels C and D). There was no evidence of an interaction between these two main experimental regimens (Panels A & B); interaction p = 0.37 for OS.
Gynecologic Oncology  , DOI: ( /j.ygyno )
Copyright © 2019 The Authors Terms and Conditions